BioTuesdays

Profound Medical to list on OTCQX

Shares of Profound Medical (TSX-V:PRN) will be eligible for trading on the OTCQX Best Market under the symbol, PRFMF, effective at the open on March 13.

“The U.S. is a key target market for the TULSA-PRO system and many of our shareholders are U.S.-based,” CEO, Dr. Arun Menawat, said in a statement.

“Accordingly, this OTCQX listing is a natural evolution for Profound, which should increase our visibility and complement our efforts to broaden our U.S. shareholder base,” he added.

TULSA-PRO system uses real-time MRI, with temperature feedback, in conjunction with ultrasound to deliver thermal energy to the prostate in order to ablate tissue and avoid side-effects.

Profound is currently conducting a pilot commercial launch of TULSA-PRO system in key European and other CE mark jurisdictions.

The company is also sponsoring a multicenter, prospective FDA-registered clinical trial, TACT, which if successful, would support Profound’s application to the FDA for approval to market the TULSA-PRO system in the U.S.

Profound Medical’s common shares will continue to trade on the TSX Venture Exchange under its existing symbol, PRN.

Subscribe

Sign up to our weekly BioTuesdays newsletter.

Subscribe

Sign up to our weekly BioTuesdays newsletter.